A symbiotic collaboration between academia and industry which leverages AI to positively impact human health and support the next generation of medical breakthroughs. The MIT-Takeda Programme is part of the Abdul Latif Jameel Clinic for Machine Learning in Health.
The MIT-Takeda Program was launched in 2020 within the Abdul Latif Jameel Clinic, the epicentre of AI and healthcare at MIT, to support MIT members working at the intersection of artificial intelligence (AI) and human health. A collaboration between MIT’s School of Engineering and Takeda Pharmaceutical Company Limited, the programme seeks to leverage the combined expertise of both organisations to support MIT and Jameel Clinic faculty, students, researchers and staff working at the nexus of AI and human health, ensuring they can devote their energies to expanding the limits of knowledge and imagination.
The programme was designed to coalesce disparate disciplines, merge theory and practical implementation, combine algorithm and hardware innovations and create multidimensional collaborations between academia and industry. To this end, the programme has produced joint research efforts on topics such as automated inspection in sterile pharmaceutical manufacturing and machine learning for liver phenotyping.
A second core aim of the programme is to build a community dedicated to next generation of AI and system-level breakthroughs through the creation educational opportunities. Every year, Takeda funds fellowships to support graduate students pursuing research related to health and AI. Previous fellows have worked on an array of research topics including electronic health record systems, remote sensing data as it relates to environmental health risk and neural networks for the development of antibiotics. The latest cohort of 2022-23 Takeda Fellows are developing research in similar areas in addition to robotic control to pandemic preparedness and traumatic brain injuries.